Stem cell factor: Biology and relevance to clinical practice

Acta Haematologica

Volumn 105, Issue 3, 2001, Pages 143-150

  Smith, M A ^a   Pallister, C J ^b   Smith, J G ^a,b  

^a ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

Aplastic anaemia; Ex vivo; Expansion; Haemopoiesis; PBSC mobilisation; Stem cell factor

Indexed keywords

STEM CELL FACTOR;

ANAPHYLAXIS; APLASTIC ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CELL MIGRATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; HEMATOPOIESIS; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE;

ANIMALS; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HUMANS; PROTO-ONCOGENE PROTEINS C-KIT; STEM CELL FACTOR;

EID: 0034924333     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046556     Document Type: Article

References (65)

1. Dominant spotting, patch, and rump-white
2. A murine monoclonal antibody specific for a cell-surface antigen expressed by a sub-group of human myeloid leukaemias
3. A murine monoclonal antibody to an acute myeloid leukaemia-associated cell surface antigen identifies tissue mast cells
4. A monoclonal antibody to a human mast cell/myeloid leukaemia-specific antigen binds to normal haemopoietic progenitor cells and inhibits colony formation in vitro
5. Monoclonal antibody YB5.B8 identifies the human c-KIT protein product
6. A new acute transforming feline retrovirus and relationship of its oncogene v-KIT with the protein kinase gene family
7. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand
8. The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-KIT receptor, the gene product of the W locus
9. Primary structure and functional expression of rat and human stem cell factor DNAs
10. Identification of a ligand for the c-KIT proto-oncogene
11. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms
12. The biology of stem cell factor and its receptor c-KIT
13. Cloning and structural analysis of the human c-KIT gene
14. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis
15. IL-4 regulates c-KIT proto-oncogene product expression in human mast and myeloid progenitor cells
16. Transforming growth factor-beta regulates c-KIT message stability and cell-surface protein expression in hematopoietic progenitors
17. Inhibition of stem cell factor-induced proliferation of primitive murine hematopoietic progenitor cells signaled through the 75-kilodalton tumor necrosis factor receptor: Regulation of c-KIT and p53 expression
18. Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells
19. Modulation of c-KIT mRNA and protein by hemopoietic growth factors
20. Downregulation of c-KIT expression in human endothelial cells by inflammatory stimuli
21. Growth factors and their receptors in haemopoiesis
22. C-KIT proto-oncogene exon 8 inframe deletion plus insertion mutations in acute myeloid leukaemia
23. Early signaling pathways activated by c-KIT in hematopoietic cells
24. Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells
25. Identification and characterization of a soluble c-KIT receptor produced by human hematopoietic cell lines
26. The majority of stem cell factor exists as monomer under physiological conditions
27. Soluble c-KIT molecule in serum from healthy individuals and patients with haemopoietic disorders
28. Expression of the YB5.B8 antigen (c-KIT proto-oncogene product) in normal human bone marrow
29. Isolation of c-KIT receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: Functional properties and composite antigenic profile
30. Effects of the stem cell factor, c-KIT ligand, on human megakaryocytic cells
31. Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues
32. Stem cell factor and hematopoiesis
33. c-KIT ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
34. A c-KIT ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrow of baboons
35. In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow haemopoietic stem cells
36. Ex vivo expansion CD34+/CAL133+ selected autologous peripheral blood progenitor cells (PBPC) in high-risk breast cancer patients receiving intensive chemotherapy
37. Ex vivo expansion of CD34+/CD41+ late progenitors from enriched peripheral blood CD34+ cells
38. Comparison of different methods for separation and ex vivo expansion of cord blood progenitor cells
39. Ex vivo expansion of CD34+ umbilical cord blood cells in a defined serum-free medium (QBSF-60) with early effect cytokines
40. Effective ex vivo generation of granulopoietic post-progenitor cells from mobilized peripheral blood CD34+ cells
41. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo
42. Steel factor influences the distribution and activity of murine hematopoietic stem cells in vivo
43. Coexpression of two fibronectin receptors, VLA-4 and VLA-5, by immature human erythroblastic precursor cells
44. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells
45. Fibronectin and VLA-4 in haematopoietic stem-cell-microenvironment interactions
46. Stem cell factor modulates avidity of a4b1 and a5b1 integrins expressed on hematopoietic cell lines
47. Leukocyte-endothelial adhesion molecules
48. Management strategies for the hard-to-mobilise patient
49. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients
50. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients: Results of a phase I/II trial
51. The utilisation of cytokines in stem cell mobilisation
52. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans
53. Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy
54. Increased numbers of long-term-culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor
55. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anaemia
56. Cytokine mRNA expression of bone marrow stromal cells from patients with aplastic anaemia and myelodysplastic syndrome
57. The expression of cytokine and cytokine receptor genes in long term bone marrow culture in congenital and acquired marrow hypoplasias
58. A severe and consistent deficit in marrow circulating primitive haemopoietic cells (long-term culture initiating cells) in acquired aplastic anaemia
59. Increased apoptosis in aplastic anemia bone marrow progenitor cells: Possible pathophysiological significance
60. The membrane-bound isoform of stem cell factor synergizes with soluble Flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic bone marrow
61. In aplastic anemia progenitor cells have a reduced sensitivity to the effects of growth factors
62. Use of stem cell factor (Stemgen, SCF) and filgrastim (G-CSF) in aplastic anaemia (AA) patients (pts) who have failed ATG/ALG therapy
63. Haemopoietic growth factors, the cell cycle of acute myeloblastic leukaemia progenitors and sensitivity to cytosine arabinoside
64. Kinetic characteristics of de novo and secondary AML cells influence their response to haemopoietic growth factor (HGF) priming and correlate with clinical outcome